

POSTER PRESENTATION

Open Access

Cutaneous adverse events associated with long-term immunomodulating therapy in multiple sclerosis

Deepak MW Balak^{1*}, Gerald JD Hengstman^{2,3}, Raymond Hupperts⁴, H Bing Thio¹

From 6th European Workshop on Immune-Mediated Inflammatory Diseases Nice, France. 23-25 November 2011

Introduction

Multiple sclerosis (MS) is a common immune-mediated inflammatory disease of the central nervous system that causes severe neurological disability [1]. Treatment is aimed at reducing disease progression via modulation of the immune system with disease-modifying therapies (DMTs) such as glatiramer acetate (GA) and interferon beta (IFN beta) [2]. Skin reactions to DMT are common and involve localized inflammatory processes [3].

Aim

Our aim was to assess the prevalence and type of cutaneous adverse events associated with long-term use of DMT.

Methods

A cross-sectional study was conducted in 2010-2011 among 15 clinics in the Netherlands. Eligible for inclusion were MS patients who were treated with their first DMT for at least 2 years. All consecutive eligible patients willing to participate were enrolled, irrespective of the presence of skin reactions. Skin reactions were assessed from digital photographs of the injection-sites by dermatologists, who were blinded for the DMT.

Results

A total of 146 patients were enrolled. The median age was 47 years (interquartile range [IQR] 41-54 years) and most patients (76%) were female. The median duration of DMT treatment was 4 years (IQR 3-8). Forty-four (30%) patients were treated with intramuscular (IM) IFN beta-1a, 43 (29%) with subcutaneous (SC) IFN beta-1a,

38 (26%) with IFN beta-1b, and 21 (14%) with GA. The proportion of patients with cutaneous adverse events was 40%, 77%, 63%, and 81% among patients receiving IM IFN beta-1a, SC IFN beta-1a, SC IFN beta-1b, and GA, respectively. Skin reactions were local injection-site reactions (61%), lipoatrophy (24%), healed skin ulcers (7%), postinflammatory hyperpigmentation (4%), urticaria (3%), and skin necrosis (1%).

Conclusion

The prevalence of cutaneous adverse events associated with DMT treatment was high. The most common skin reactions were local injection-site reactions and lipoatrophy related to panniculitis.

Author details

¹Dept. of Dermatology, Erasmus Medical Center, Rotterdam, The Netherlands. ²Dept. of Neurology, Catharina Ziekenhuis, Eindhoven, The Netherlands. ³Regionaal MS Centrum Oost-Brabant, Eindhoven, The Netherlands. ⁴Academic MS Centre Limburg, Orbis Medical Centre, Sittard, The Netherlands.

Published: 23 November 2011

References

- Frohman EM, Racke MK, Raine CS: Multiple sclerosis—the plaque and its pathogenesis. N Engl J Med 2006, 354(9):942-55.
- 2. Compston A, Coles A: Multiple sclerosis. Lancet 2008, 372(9648):1502-17.
- Buttmann M, Goebeler M, Toksoy A, Schmid S, Graf W, Berberich-Siebelt F, Rieckmann P: Subcutaneous interferon-beta injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction. J Neuroimmunol 2005, 168(1-2):175-82.

doi:10.1186/1479-5876-9-S2-P14

Cite this article as: Balak *et al.*: Cutaneous adverse events associated with long-term immunomodulating therapy in multiple sclerosis. *Journal of Translational Medicine* 2011 **9**(Suppl 2):P14.

¹Dept. of Dermatology, Erasmus Medical Center, Rotterdam, The Netherlands Full list of author information is available at the end of the article

